Alkermes (ALKS) Stock Price Target Raised to $53 by Mizuho
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowMizuho increased its price target for Alkermes (ALKS) to $53, attributing the change to improved confidence in the company's drug pipeline. This revision reflects optimism regarding potential therapeutic advancements. The adjustment is significant for investors monitoring ALKS, as price targets can influence market sentiment and trading decisions. Increased confidence in drug development may correlate with higher stock valuations moving forward.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
